CytoMed Therapeutics Has Acquired The License And Certain Assets Of Cellsafe International, A Malaysian Cord Blood Bank, Deal Terms Were Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
CytoMed Therapeutics has acquired the license and assets of Cellsafe International, a Malaysian cord blood bank. This acquisition includes a cord blood banking license, cryopreservation equipment, and real estate, enhancing CytoMed's cell therapy strategy.
October 03, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CytoMed Therapeutics has acquired Cellsafe International's assets, including a cord blood banking license and cryopreservation equipment, to enhance its cell therapy strategy.
The acquisition provides CytoMed with valuable assets and a strategic advantage in cell therapies, likely boosting investor confidence and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100